Transdermal testosterone delivery: testosterone patch and gel

被引:28
作者
Gooren, LJG [1 ]
Bunck, MCM [1 ]
机构
[1] VU Univ Med Ctr, Dept Endocrinol, Sect Androl, NL-1007 MB Amsterdam, Netherlands
关键词
androgen replacement therapy; testosterone patch; testosterone gel; hypogonadism;
D O I
10.1007/s00345-003-0368-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Testosterone replacement treatment is usually life-long. Fortunately, testosterone administration is relatively safe and until the age of 50 years few side effects are noted with normal doses of testosterone. After the age of 50 years when prostate disease becomes more prevalent, shorter-acting testosterone preparations, allowing a fast reduction of circulating testosterone levels, may be an advantage. Testosterone has an impact on sexual and non-sexual behaviour and short-acting testosterone preparations may be better suited for the initiation of long-term administration allowing the monitoring of behavioural effects. Testosterone can be delivered to the circulation through the intact skin, both genital and non-genital. Transdermal administration delivers testosterone at a controlled rate into the systemic circulation, avoiding hepatic first pass and reproducing the diurnal rhythm of testosterone secretion and without the peak and trough levels observed with the use of the traditional long-acting testosterone injections. In conclusion, both the testosterone patch and testosterone gel are valuable contributions to androgen replacement treatment meeting the requirements specified for testosterone replacement treatment.
引用
收藏
页码:316 / 319
页数:4
相关论文
共 19 条
[1]
Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system [J].
Arver, S ;
Dobs, AS ;
Meikle, AW ;
Allen, RP ;
Sanders, SW ;
Mazer, NA .
JOURNAL OF UROLOGY, 1996, 155 (05) :1604-1608
[2]
Atkinson LE, 1998, TESTOSTERONE ACTION, P365
[3]
Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years [J].
Behre, HM ;
von Eckardstein, S ;
Kliesch, S ;
Nieschlag, E .
CLINICAL ENDOCRINOLOGY, 1999, 50 (05) :629-635
[4]
Issues in testosterone replacement in older men [J].
Bhasin, S ;
Bagatell, CJ ;
Bremner, WJ ;
Plymate, SR ;
Tenover, JL ;
Korenman, SG ;
Nieschlag, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (10) :3435-3448
[5]
TRANSDERMAL DIHYDROTESTOSTERONE TREATMENT OF ANDROPAUSE [J].
DELIGNIERES, B .
ANNALS OF MEDICINE, 1993, 25 (03) :235-241
[6]
Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim™, compared to AndroGel® [J].
Marbury, T ;
Hamill, E ;
Bachand, R ;
Sebree, T ;
Smith, T .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2003, 24 (03) :115-120
[7]
Transdermal testosterone [J].
McClellan, KJ ;
Goa, KL .
DRUGS, 1998, 55 (02) :253-258
[8]
A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function [J].
McNicholas, TA ;
Dean, JD ;
Mulder, H ;
Carnegie, C ;
Jones, NA .
BJU INTERNATIONAL, 2003, 91 (01) :69-74
[9]
ENHANCED TRANSDERMAL DELIVERY OF TESTOSTERONE ACROSS NONSCROTAL SKIN PRODUCES PHYSIOLOGICAL CONCENTRATIONS OF TESTOSTERONE AND ITS METABOLITES IN HYPOGONADAL MEN [J].
MEIKLE, AW ;
MAZER, NA ;
MOELLMER, JF ;
STRINGHAM, JD ;
TOLMAN, KG ;
SANDERS, SW ;
ODELL, WD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03) :623-628
[10]
MEIKLE AW, 1998, TESTOSTERONE ACTION, P389